Bristol-Myers Squibb Live Stock Price Today, Share Analysis and Chart

Name: Bristol-Myers Squibb Co.: Is Infosys Ltd. worth buying?
Item: Bristol-Myers Squibb Co.
Rating: 2.528333375
Author: Trendlyne DVM scores

Mid-range Performer

about

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol deriv...

56.77 0.38 (0.67%)

33.51% Gain from 52W Low

7.6M

XNYS Volume

XNYS 14 May, 2026 5:30 PM (EDT)

Inks Deal

Bristol Myers Squibb inks up to $15 billion deal with Hengrui for 13 early-stage drug programs See details

Medium Financial Strength

50.0 / 100

Affordable Valuation

53.2 / 100

Technically Neutral

49.1 / 100

Mid-range Performer These stocks have affordable valuations, but mid range financials and momentum View Similar Embed DVM

1Yr Price target upside is 11%

25 analysts

Bristol-Myers Squibb Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Bristol-Myers Squibb Live Stock Price Today, Share Analysis and Chart

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol deriv...

33.51% Gain from 52W Low

SWOT Analysis

Bristol-Myers Squibb Live Price Chart